AE(s)	Adverse effect(s)
AKT	Protein kinase B
ATC	Anaplastic thyroid cancer
c-KIT	Stem cell factor receptor
DTC	Differentiated thyroid cancer
EGFR	Epidermal growth factor receptor
ERK	Mitogen-activated protein kinase
FGFR	Fibroblast growth factor receptor
FLT-3	FMS-like tyrosine kinase 3
FTC	Follicular thyroid cancer
HCC	Hürthle cell carcinoma
HIF	Hypoxia-inducible factor
MEK	Mitogen-activated protein kinase kinase
MET	Hepatocyte growth factor receptor
MKI(s)	Multikinase inhibitor(s)
MTC	Medullary thyroid cancer
mTOR	Mammalian target of rapamycin
N/A	Not available
N/R	Not reached
OS	Overall survival
PDGFR	Platelet-derived growth factor receptor
PDTC(s)	Poorly differentiated thyroid cancer(s)
PFS	Progression-free survival
PGF	Placental growth factor
PI3K	phosphoinositide 3-kinase
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PTC	Papillary thyroid cancer
RAF	Rapidly accelerated fibrosarcoma kinase
RAI	Radioactive iodine
RAS	Rat sarcoma protein
RET	Rearranged during transfection
RECIST	Response Evaluation Criteria in Solid Tumors
RR	Response rate
TSH	Thyroid-stimulating hormone
VEGF	Vascular endothelial growth factor
VEGFR	Vascular endothelial growth factor receptor
VHL	Von Hippel–Lindau tumor suppressor